{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.7","value":"333"},{"groupId":"OG001","spread":"38.0","value":"541"},{"groupId":"OG002","spread":"37.0","value":"1060"},{"groupId":"OG003","spread":"45.6","value":"2190"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A. MTX was administered orally as background therapy.","id":"OG000","title":"1mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nParticipants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 2 mg LY3009104 BID in Part B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nParticipants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 4 mg LY3009104 QD in Part B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B. MTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least 1 dose of LY3009104 with evaluable LY3009104 PK data.","reportingStatus":"POSTED","timeFrame":"Baseline through 24 weeks","title":"Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104","type":"SECONDARY","unitOfMeasure":"nanomoles*hour/Liter (nmol*h/L)"}